103 related articles for article (PubMed ID: 17446684)
1. Increased inhibitory capacity of an anti-C5a complementary peptide following acetylation of N-terminal alanine.
Okada N; Asai S; Hotta A; Miura N; Ohno N; Farkas I; Hau L; Okada H
Microbiol Immunol; 2007; 51(4):439-43. PubMed ID: 17446684
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5a.
Fujita E; Farkas I; Campbell W; Baranyi L; Okada H; Okada N
J Immunol; 2004 May; 172(10):6382-7. PubMed ID: 15128829
[TBL] [Abstract][Full Text] [Related]
3. Novel complementary peptides to target molecules.
Okada H; Imai M; Ono F; Okada A; Tada T; Mizue Y; Terao K; Okada N
Anticancer Res; 2011 Jul; 31(7):2511-6. PubMed ID: 21873168
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic peptides against human anaphylatoxin C5a.
Kaneko Y; Okada N; Baranyi L; Azuma T; Okada H
Immunology; 1995 Sep; 86(1):149-54. PubMed ID: 7590876
[TBL] [Abstract][Full Text] [Related]
5. C5a inhibitor protects against ischemia/reperfusion injury in rat small intestine.
Tuboly E; Futakuchi M; Varga G; Érces D; Tőkés T; Mészáros A; Kaszaki J; Suzui M; Imai M; Okada A; Okada N; Boros M; Okada H
Microbiol Immunol; 2016 Jan; 60(1):35-46. PubMed ID: 26576826
[TBL] [Abstract][Full Text] [Related]
6. Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.
Kawai M; Quincy DA; Lane B; Mollison KW; Luly JR; Carter GW
J Med Chem; 1991 Jul; 34(7):2068-71. PubMed ID: 2066977
[TBL] [Abstract][Full Text] [Related]
7. Biologic activity of synthetic analogues of C5a anaphylatoxin.
Ember JA; Sanderson SD; Taylor SM; Kawahara M; Hugli TE
J Immunol; 1992 May; 148(10):3165-73. PubMed ID: 1578141
[TBL] [Abstract][Full Text] [Related]
8. Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory activities.
Sanderson SD; Kirnarsky L; Sherman SA; Ember JA; Finch AM; Taylor SM
J Med Chem; 1994 Sep; 37(19):3171-80. PubMed ID: 7932541
[TBL] [Abstract][Full Text] [Related]
9. Anti-C5a complementary peptide ameliorates acute peritoneal injury induced by neutralization of Crry and CD59.
Mizuno T; Mizuno M; Imai M; Suzuki Y; Kushida M; Noda Y; Maruyama S; Okada H; Okada N; Matsuo S; Ito Y
Am J Physiol Renal Physiol; 2013 Dec; 305(11):F1603-16. PubMed ID: 23904221
[TBL] [Abstract][Full Text] [Related]
10. Improvements in the minimum binding sequence of C5a: examination of His-67.
Or YS; Clark RF; Lane B; Mollison KW; Carter GW; Luly JR
J Med Chem; 1992 Jan; 35(2):402-6. PubMed ID: 1732557
[No Abstract] [Full Text] [Related]
11. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
12. Development of C5a receptor antagonists. Differential loss of functional responses.
Konteatis ZD; Siciliano SJ; Van Riper G; Molineaux CJ; Pandya S; Fischer P; Rosen H; Mumford RA; Springer MS
J Immunol; 1994 Nov; 153(9):4200-5. PubMed ID: 7930622
[TBL] [Abstract][Full Text] [Related]
13. Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.
Bubeck P; Grötzinger J; Winkler M; Köhl J; Wollmer A; Klos A; Bautsch W
Eur J Biochem; 1994 Feb; 219(3):897-904. PubMed ID: 8112341
[TBL] [Abstract][Full Text] [Related]
14. Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies.
Elsner J; Oppermann M; Kapp A
Eur J Immunol; 1996 Jul; 26(7):1560-4. PubMed ID: 8766561
[TBL] [Abstract][Full Text] [Related]
15. Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.
Fung M; Lu M; Fure H; Sun W; Sun C; Shi NY; Dou Y; Su J; Swanson X; Mollnes TE
Clin Exp Immunol; 2003 Aug; 133(2):160-9. PubMed ID: 12869020
[TBL] [Abstract][Full Text] [Related]
16. A second stimulus required for enhanced antifungal activity of human neutrophils in blood is provided by anaphylatoxin C5a.
Hünniger K; Bieber K; Martin R; Lehnert T; Figge MT; Löffler J; Guo RF; Riedemann NC; Kurzai O
J Immunol; 2015 Feb; 194(3):1199-210. PubMed ID: 25539819
[TBL] [Abstract][Full Text] [Related]
17. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
Oppermann M; Götze O
Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
[TBL] [Abstract][Full Text] [Related]
18. [Study for an allergic inflammation model using human lungs and its pharmacological application].
Hama H; Ono N; Abe M
Yakugaku Zasshi; 2007 Apr; 127(4):721-7. PubMed ID: 17409703
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the tissue distribution of the rat C5a receptor and inhibition of C5a-mediated effects through the use of two MoAbs.
Rothermel E; Götze O; Zahn S; Schlaf G
Scand J Immunol; 2000 Oct; 52(4):401-10. PubMed ID: 11013012
[TBL] [Abstract][Full Text] [Related]
20. Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor.
Cain SA; Coughlan T; Monk PN
Biochemistry; 2001 Nov; 40(46):14047-52. PubMed ID: 11705397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
